Literature DB >> 3700458

Urinary polyamine excretion by tumor-bearing and tumor-free mice exposed to cyclophosphamide, 5-fluorouracil and 6-mercaptopurine.

H Osswald, R Herrmann, G R Jones, D Kitta, W Kunz.   

Abstract

The effects of cytostatic treatment on urinary polyamine excretion have been investigated in tumor-bearing (either Ehrlich carcinoma of S 180 sarcoma) and in tumor-free mice. The animals were exposed to single or multiple treatment with various doses of cyclophosphamide, 5-fluorouracil, or 6-mercaptopurine. Treatment invariably enhanced polyamine excretion dependent on dose and effectiveness of the cytostatic drug. The most pronounced increases were observed in the excretion of spermine and putrescine, with peak excretion usually occurring after 1-2 and 3-4 days, respectively. The urinary excretion of spermidine was relatively modest in untreated mice, but the increases observed following drug treatment were high in proportion. Significant differences in urinary polyamine excretion were observed between tumor-free and tumor-bearing animals following treatment with all cytostatic agents. Peak values were invariably higher in tumor-bearing mice even in those with small, barely detectable tumors. After discontinuation of treatment polyamine excretion returned to normal values and stabilized in groups in which regression predominated, whereas in those groups of animals which showed little or no tumor regression urinary polyamine levels gradually increased again during a 2-week observation period.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700458     DOI: 10.1007/bf00400753

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Polyamine excretion in the urine of cancer patients.

Authors:  F Dreyfuss; R Chayen; G Dreyfuss; R Dvir; J Ratan
Journal:  Isr J Med Sci       Date:  1975-08

2.  Imbalance in ornithine metabolism in hepatomas of different growth rates as expressed in formation of putrescine, spermidine, and spermine.

Authors:  H G Williams-Ashman; G L Coppoc; G Weber
Journal:  Cancer Res       Date:  1972-09       Impact factor: 12.701

3.  [Microdetermination of spermine and spermidine as 1-dimethylaminonaphthalene-5-sulfonic acid derivtives].

Authors:  N Seiler; M Wiechmann
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1967-10

4.  Changes in serum putrescine and spermidine levels following local radiation to hepatoma 3924A of the rat.

Authors:  D H Russell; W B Looney; C J Kovacs; H A Hopkins; J W Dattilo; H P Morris
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

5.  The relationship of polyamines in cerebrospinal fluid to the presence of central nervous system tumors.

Authors:  L J Marton; O Heby; V A Levin; W P Lubich; D C Crafts; C B Wilson
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

6.  [Polyamines and their significance for control of cancer chemotherapy (author's transl)].

Authors:  E Nissen; R Dettmer; D Fiedler; M Bodammer
Journal:  Arch Geschwulstforsch       Date:  1980

7.  Polyamines as markers of response and disease activity in cancer chemotherapy.

Authors:  B G Durie; S E Salmon; D H Russell
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

8.  Polyamines in malignant melanoma. Urinary excretion and disease progress.

Authors:  R M Townsend; P W Banda; L J Marton
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

Review 9.  Clinical relevance of polyamines.

Authors:  D H Russell
Journal:  Crit Rev Clin Lab Sci       Date:  1983       Impact factor: 6.250

10.  Increased polyamine concentrations in the urine of human cancer patients.

Authors:  D H Russell
Journal:  Nat New Biol       Date:  1971-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.